Xenon Gas Shows Promise as Potential Alzheimer's Treatment in Mouse Study

Researchers report that inhaling xenon gas reduced brain inflammation and improved cognitive function in mice, with human trials set to begin soon.

A new study suggests that inhaling xenon gas can reduce neuroinflammation, brain atrophy, and cognitive decline in mouse models of Alzheimer's disease.
Xenon gas was found to activate microglia, the brain's immune cells, helping clear amyloid plaques and reduce tau protein buildup, both hallmarks of Alzheimer's.
The gas crosses the blood-brain barrier, a key challenge in Alzheimer's treatment, and showed protective effects in multiple mouse models of the disease.
A Phase 1 clinical trial to test the safety of xenon gas in healthy human volunteers is set to begin in early 2025 at Brigham and Women's Hospital.
Researchers are also exploring the potential of xenon gas for treating other neurodegenerative and neuronal loss diseases, such as multiple sclerosis and ALS.